Loading company financials…
Nasdaq · Biological Products, (No Diagnostic Substances) · CIK 0000875045
$220.83
+1.07% · delayed 15 min
$32.42B market value
What this company does
BIOGEN develops and makes medicines. It took in $9.89B last year, which makes it a mid-sized company. Of every dollar it sells, about 13 cents is left as profit.
Financial health
Strong finances across the board.
From BIOGEN INC.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
of 9 checks passed
Measured against FY2024, from the 10-K
Deteriorated: -20.8%
$1.63B to $1.29B
Deteriorated: −3.8 pts
16.9% to 13.1%
Deteriorated: -24.7%
$2.72B to
It makes a profit rather than burning through money.
$1.29B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$2.20B cash from operations
Its debt is small next to the cash the business produces.
about 1.5 years of cash flow to clear
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 3.49
It keeps less of each sale as profit than it did a year ago.
16.9% → 13.1%
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 4% a year for the next 10 years. Over the last 10 years it shrank by about 5% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $1.29B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $1.29B and generated $2.20B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-07-29 | 2026-06-30 |
| Major event announcement(8-K) | 2026-07-29 | 2026-07-29 |
Financial figures are from BIIB's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
Nine yes-or-no tests of whether this year's finances improved on last year's.
3.49
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +26.7%
$2.38B to $3.01B
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 2% and 6%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Barely. Sales were roughly flat, up 2.2%.
No. At its current cash flow it could clear its debt in about 1.5 years. For every $1 it owes, it owns $2.63 in assets.
Around average. Investors pay $25.1 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-01 | 2026-07-01 |
| Major event announcement(8-K) | 2026-06-10 | 2026-06-09 |
| Major event announcement (amended)(8-K/A) | 2026-06-10 | 2026-05-14 |
| Major event announcement(8-K) | 2026-05-14 | 2026-05-14 |
| Quarterly report(10-Q) | 2026-04-29 | 2026-03-31 |
| Major event announcement(8-K) | 2026-04-29 | 2026-04-29 |
| Shareholder voting information(DEF 14A) | 2026-04-28 | 2026-06-09 |
| Major event announcement(8-K) | 2026-04-06 | 2026-04-06 |
| Major event announcement(8-K) | 2026-03-31 | 2026-03-31 |
| Major event announcement(8-K) | 2026-03-11 | 2026-03-11 |
| Major event announcement(8-K) | 2026-02-11 | 2026-02-11 |
| Annual report(10-K) | 2026-02-06 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-06 | 2026-02-06 |
| Major event announcement(8-K) | 2026-01-14 | 2026-01-13 |
| Quarterly report(10-Q) | 2025-10-30 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Major event announcement(8-K) | 2025-10-14 | 2025-10-14 |
| Major event announcement(8-K) | 2025-07-31 | 2025-07-31 |
Coverage from the last 30 days
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Yahoo Finance ·
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Yahoo Finance ·
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data
Yahoo Finance ·
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet
Yahoo Finance ·
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
Yahoo Finance ·
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Yahoo Finance ·
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Yahoo Finance ·
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Yahoo Finance ·
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says
Yahoo Finance ·
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Yahoo Finance ·
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Yahoo Finance ·
Primary sources and further research